Insight Molecular Diagnostics I IMDX
Price alert —
Sign in to get a one-time email the moment IMDX crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · IMDX
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -13406.2% | -32284.4% |
| 2025-12-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -2015.4% | -873.6% |
| 2025-09-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -4174.6% | -2950.0% |
| 2025-06-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -1880.7% | -1345.8% |
| 2025-03-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -312.0% | -276.9% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare IMDX vs peers
Line IMDX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with IMDX
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 0 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
No earnings history available.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| IMDX ★ | $0B | — | -6.1 | 78.5 | -3.9 | -14.3 | 51.1% | -98.5% | — | -10.23% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 56.26%
| Holder | Shares | % out |
|---|---|---|
| Broadwood Capital, Inc. | 11,931,839 | 36.95% |
| AWM Investment Company, Inc. | 2,806,256 | 8.69% |
| Pura Vida Investments, Llc | 947,134 | 2.93% |
| Alyeska Investment Group, L.p. | 840,777 | 2.60% |
| Vanguard Capital Management LLC | 537,161 | 1.66% |
| Heights Capital Management, Inc | 392,545 | 1.22% |
| Geode Capital Management, LLC | 262,053 | 0.81% |
| FNY Investment Advisers, LLC | 182,561 | 0.57% |
| Blackrock Inc. | 135,345 | 0.42% |
| Vanguard Fiduciary Trust Co | 132,591 | 0.41% |
Insider activity · 90d
11 buys / 0 sells · ratio 11.0 · Finnhub
- Last Andrew J. F 58,752 @ $5.69
- Arno Andrew F 156,785 @ $5.69
- SILVERMAN LOU F 55,807 @ $5.69
- Last Andrew J. BUY 66,452
- Arno Andrew BUY 168,885
- SILVERMAN LOU BUY 63,507
- BROADWOOD PARTNERS, L.P. BUY 12,684,884
- BROADWOOD PARTNERS, L.P. BUY 12,684,884 @ $3.64
- BROADWOOD PARTNERS, L.P. BUY 12,433,961
- BROADWOOD PARTNERS, L.P. BUY 12,433,961 @ $3.53
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-06 | 4 | view · |
| 4 | 2026-07-06 | 4 | view · |
| 4 | 2026-07-06 | 4 | view · |
| 8-K | 2026-06-17 | 8-K | view · |
| 4 | 2026-06-15 | 4 | view · |
| 4 | 2026-06-15 | 4 | view · |
| 4 | 2026-06-15 | 4 | view · |
| 10-Q | 2026-05-13 | 10-Q | view · |
| 8-K | 2026-05-13 | 8-K | view · |
| DEF 14A | 2026-04-30 | DEF 14A | view · |
| 8-K | 2026-04-30 | 8-K | view · |
| 4 | 2026-04-27 | Insider transaction (Form 4) | view · |
| 4 | 2026-04-20 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-30 | Insider transaction (Form 4) | view · |
| 4 | 2026-03-30 | 4 | view · |
| 4 | 2026-03-30 | Insider transaction (Form 4) | view · |
| 10-K | 2026-03-26 | 10-K | view · |
| 8-K | 2026-03-26 | 8-K | view · |
| 8-K | 2026-02-26 | 8-K | view · |
| 4 | 2026-02-12 | Insider transaction (Form 4) | view · |
| 8-K | 2026-02-12 | 8-K | view · |
| 8-K | 2026-02-11 | 8-K | view · |
| 10-Q | 2025-11-10 | 10-Q | view · |
| 8-K | 2025-11-10 | 8-K | view · |
| 4 | 2025-11-04 | 4 | view · |
| 8-K | 2025-10-02 | 8-K | view · |
| 4 | 2025-09-30 | 4 | view · |
| 4 | 2025-09-30 | 4 | view · |
| 4 | 2025-09-30 | 4 | view · |
| 8-K | 2025-09-19 | 8-K | view · |
| 10-Q | 2025-08-11 | 10-Q | view · |
| 8-K | 2025-08-11 | 8-K | view · |
| 4 | 2025-07-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-07-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-07-03 | Insider transaction (Form 4) | view · |
| 8-K | 2025-07-02 | 8-K | view · |
| 8-K | 2025-06-17 | 8-K | view · |
| DEF 14A | 2025-05-14 | DEF 14A | view · |
| 10-Q | 2025-05-12 | 10-Q | view · |
| 8-K | 2025-05-12 | 8-K | view · |
| 8-K | 2025-04-17 | Material event (8-K) | view · |
| S-1 | 2025-03-28 | Registration / IPO (S-1) | view · |
| 4 | 2025-03-28 | Insider transaction (Form 4) | view · |
| 4 | 2025-03-28 | Insider transaction (Form 4) | view · |
| 4 | 2025-03-28 | Insider transaction (Form 4) | view · |
| 10-K | 2025-03-24 | 10-K | view · |
| 8-K | 2025-03-24 | Material event (8-K) | view · |
| 8-K | 2025-03-10 | Material event (8-K) | view · |
| 4 | 2025-02-11 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-11 | Insider transaction (Form 4) | view · |
| 4 | 2025-02-10 | Insider transaction (Form 4) | view · |
| 8-K | 2025-02-10 | Material event (8-K) | view · |
| 4 | 2025-02-04 | Insider transaction (Form 4) | view · |
| 4 | 2025-01-31 | Insider transaction (Form 4) | view · |
| 4 | 2025-01-15 | Insider transaction (Form 4) | view · |
| 8-K | 2025-01-08 | Material event (8-K) | view · |
| 4 | 2024-12-27 | Insider transaction (Form 4) | view · |
| 4 | 2024-12-26 | Insider transaction (Form 4) | view · |
| 4 | 2024-12-09 | Insider transaction (Form 4) | view · |
| 10-Q | 2024-11-12 | 10-Q | view · |
About IMDX
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a coll…
Options picks · IMDX
ITM + OTM ideas from the latest scanLoading…
Congress trades · IMDX
STOCK Act disclosuresLoading…
SEC filings & insiders · IMDX
EDGAR · liveLoading…
Holders · IMDX
Institutions & insider activityLoading…